The use of therapeutic apheresis in very low weight patients is generally thought to have limitations, because of possible severe adverse reactions, potential risk related to the extracorporeal procedure, due to the low weight of the young patients. A careful therapeutic approach using appropriate precautions, and also introducing modifications to the standard procedure, can minimise the risk without compromising the efficacy of the plasmapheresis. The aim of the study was to evaluate apheresis tolerance and acceptability in children [Artif. Organs. 21 (1997) 1126] and infants [J. Clin. Apheresis 5 (1989) 21] with inherited lipid metabolism disorder, familial hypercholesterolemia (FH), primary hyperlipoproteinemia (lipoprotein phenotype I), and acute leukemia, weighing on average 20.55 kg. One thousand one hundred twenty three aphereses were completed. Three types of apheresis were performed: leukapheresis, plasma exchange, dextran sulphate cellulose (DSC) low density lipoprotein (LDL)-apheresis. Three different types of continuous flow systems were used. Technical adaptation depending on patients blood volume, body mass index, hematocrit, type of system used, permitted us to perform complete aphereses, obtaining a high degree of tolerance and acceptability of the treatment. The use of plasmapheresis is regarded to be an extreme therapeutic measure in children. However, when the need for such treatment is undebatable, plasmapheresis must be done. A well-trained and experienced team can overcome the technical difficulties in order to complete the procedures without complications. The most frequently observed adverse effects are vascular relative access insufficiency (2.0%), and mild hypotension (2.0%). © 2004 Elsevier Ltd. All rights reserved.

Stefanutti, C., Lanti, A., Di Giacomo, S., Mareri, M., De Lorenzo, F., Landolfo, A., et al. (2004). Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. TRANSFUSION AND APHERESIS SCIENCE, 31(1), 3-10 [10.1016/j.transci.2004.01.010].

Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks

ISACCHI, GIANCARLO
2004-01-01

Abstract

The use of therapeutic apheresis in very low weight patients is generally thought to have limitations, because of possible severe adverse reactions, potential risk related to the extracorporeal procedure, due to the low weight of the young patients. A careful therapeutic approach using appropriate precautions, and also introducing modifications to the standard procedure, can minimise the risk without compromising the efficacy of the plasmapheresis. The aim of the study was to evaluate apheresis tolerance and acceptability in children [Artif. Organs. 21 (1997) 1126] and infants [J. Clin. Apheresis 5 (1989) 21] with inherited lipid metabolism disorder, familial hypercholesterolemia (FH), primary hyperlipoproteinemia (lipoprotein phenotype I), and acute leukemia, weighing on average 20.55 kg. One thousand one hundred twenty three aphereses were completed. Three types of apheresis were performed: leukapheresis, plasma exchange, dextran sulphate cellulose (DSC) low density lipoprotein (LDL)-apheresis. Three different types of continuous flow systems were used. Technical adaptation depending on patients blood volume, body mass index, hematocrit, type of system used, permitted us to perform complete aphereses, obtaining a high degree of tolerance and acceptability of the treatment. The use of plasmapheresis is regarded to be an extreme therapeutic measure in children. However, when the need for such treatment is undebatable, plasmapheresis must be done. A well-trained and experienced team can overcome the technical difficulties in order to complete the procedures without complications. The most frequently observed adverse effects are vascular relative access insufficiency (2.0%), and mild hypotension (2.0%). © 2004 Elsevier Ltd. All rights reserved.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/05 - Patologia Clinica
English
Con Impact Factor ISI
dextran sulfate; low density lipoprotein; acute leukemia; apheresis; article; blood volume; body mass; body weight; child; clinical article; disorders of lipid and lipoprotein metabolism; evaluation; familial hypercholesterolemia; feasibility study; female; hematocrit; human; hyperlipoproteinemia type 1; hypotension; infant; leukapheresis; male; patient compliance; plasmapheresis; risk; vascular access; Adolescent; Blood Component Removal; Body Weight; Child; Child, Preschool; Developmental Disabilities; Female; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Male; Patient Compliance; Thinness; Weight Gain
Children; Low weight; Therapeutic apheresis
Stefanutti, C., Lanti, A., Di Giacomo, S., Mareri, M., De Lorenzo, F., Landolfo, A., et al. (2004). Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. TRANSFUSION AND APHERESIS SCIENCE, 31(1), 3-10 [10.1016/j.transci.2004.01.010].
Stefanutti, C; Lanti, A; Di Giacomo, S; Mareri, M; De Lorenzo, F; Landolfo, A; Isacchi, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/56393
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact